To date, the R21/Matrix-M malaria vaccine has been licensed for use in Ghana, Nigeria and Burkina Faso. Read further on Dynamite News
Chief Executive Officer of Serum Institute of India (SII), Adar Poonawalla, on Tuesday announced the launch of the first made-in-India Human Papillomavirus (HPV) “CERVAVAC” vaccine, for the prevention of cervical cancer. Read full story on Dynamite News:
Raising concern on the rising COVID-19 cases in neighbouring China, Serum Institute of India (SII) CEO Adar Poonawala on Wednesday asked the people not to panic because of India’s “excellent vaccination coverage and track record”. Read on for details:
The European Medicines Agency (EMA) said it has not received any application from the COVID-19 vaccine Covishield maker Serum Institute of India (SII) for authorisation.
Serum Institute of India (SII) on Wednesday fixed the prices of Covishield vaccine at Rs 400 per dose for state governments and Rs 600 per dose for private hospitals.
Serum Institute of India (SII), the world’s biggest vaccine maker by volume, on Sunday asked for patience from foreign governments awaiting their supply of COVID-19 shots, saying it had been directed to prioritise India’s requirements.
Chief Minister Uddhav Balasaheb Thackeray is in touch with the Pune Municipal Commissioner and is taking complete on-ground updates. Full Story
Fire at the Serum Institute of India building is under control, the cooling process is underway. No casualty reported cause of the fire is still unknown. Full Story
The Serum Institute of India (SII) has applied to the Drugs Controller General of India (DCGI) seeking emergency use authorisation for its COVID-19 vaccine “Covishield” in the country.
English
English
English
